Diabetic foot ulcers (DFUs) are a devastating ailment for many diabetic patients with
increasing prevalence and morbidity. The complex pathophysiology of DFU wound …

Hypertension significantly increases the risk of cardiovascular disease. Currently, effective
standard pharmacological treatment is available in the form of diuretics, ACE inhibitors …

Nebivolol is a beta-1 receptor blocker used to treat hypertension, heart failure, erectile
dysfunction, vascular disease, and diabetes mellitus. This review investigated the data …

Nebivolol (NBV), a BCS class II anti-hypertensive drug, suffers from limited solubility and
oral bioavailability. Nanosized ethosomes were adopted as an approach to solubilize and …

Hypertension, also known as high blood pressure, is a serious medical condition that affects
billions of people worldwide. Nebivolol hydrochloride, a β1–adrenergic blocking agent, is …

Nebivolol (NEB) is a highly selective β1 receptor antagonist with a distinct pharmacological
profile. This drug is approved for the treatment of hypertension in the US, and hypertension …

Cardiovascular diseases (CVDs) are widespread in the modern world, and their number is
constantly growing. For a long time, CVDs have been the leading cause of morbidity and …

Enterovirus 71 (EV71) is an etiological agent of hand foot and mouth disease and can also
cause neurological complications in young children. However, there are no approved drugs …

According to the most recent international guidelines, β-blockers maintain a central role in
the management of hypertension, being recommended at any treatment step when there is a …

The lipid‐based drug delivery system (LBDDS) is a well‐established technique that is
anticipated to bring about comprehensive transformations in the pharmaceutical field …